SciBase Successfully Registers Rights Issue and Share Conversion in Landmark Decision

SciBase Successfully Registers Rights Issue and Share Conversion

SciBase Holding AB, a pioneering global medical technology firm specializing in dermatological diagnostics, has accomplished a significant milestone. The company announced that it has officially registered a rights issue involving new shares valued at approximately SEK 57.5 million, a decision made by the Board of Directors on September 3, 2026.

This notable rights issue, referred to as the “Rights Issue,” was fully registered with the Swedish Companies Registration Office on October 8, 2026. This action enables the company to issue new shares, thereby enhancing its capital base as it continues to focus on early detection and prevention in dermatology through its groundbreaking product, Nevisense.

The outcome of the Rights Issue was previously communicated on October 1, 2026, revealing positive response and participation from existing shareholders. A total of 3,834,487 new shares will be made available, showcasing a robust engagement in the company’s growth strategy. Notably, the last day for trading in the paid subscribed shares, or BTA, on the Nasdaq First North Growth Market is set for October 16, 2026.

Shareholders should note that the record date with Euroclear Nordics AB for the conversion of BTA into shares is scheduled for October 20, 2026. The newly issued shares are anticipated to be reflected in the respective securities and custody accounts by October 22, 2026, allowing shareholders to realize their investment promptly.

The conversion process of BTA into shares will occur automatically, which means that individual shareholders won’t need to complete any specific actions to facilitate this transition. However, those with nominee-registered holdings will be updated regarding the procedures through their respective nominees, ensuring that all shareholders remain informed.

Furthermore, as a result of the Rights Issue and a directed issue of 60,000 shares to a guarantor, SciBase's total share count will increase to 14,119,787 shares. This corresponds with a share capital of SEK 70,598,935, thereby solidifying SciBase’s financial foundation for future expansions and innovations within the dermatology sector.

SciBase's Chief Financial Officer, Michael Colérus, expressed enthusiasm regarding the registration, stating that the rights issue underscores the company’s commitment to advancing dermatological healthcare through innovative technologies. The company aims to enhance diagnostic accuracy, thus improving patient outcomes and proactive skin health management.

To optimize their funding strategies and ensure legal compliance during this process, SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers. Legal guidance is provided by BAHR, ensuring all compliance protocols are meticulously followed throughout this capital raising venture.

As SciBase moves forward, their leadership remains dedicated to minimizing patient suffering and delivering cutting-edge technologies in dermatology. Established on over two decades of research from the Karolinska Institutet in Stockholm, SciBase stands at the forefront of innovation in skin health diagnostics. The company's flagship product, Nevisense, embodies their commitment to leveraging AI and advanced technologies to transform patient care.

For further details regarding this rights issue and future developments, stakeholders are encouraged to stay connected through SciBase's investor relations platforms. The company's stock has been actively traded on Nasdaq First North Growth Market since June 2, 2015, and continuous updates are made available to the investing public for transparency and engagement.

This successful rights issue marks a significant step for SciBase, preparing the company for its next phase of growth in the medical technology landscape and strengthening its position in the healthcare market. As the company capitalizes on its innovative strengths, patients and investors alike can anticipate remarkable advancements originating from this dedicated medical technology pioneer.